101 related articles for article (PubMed ID: 16315582)
1. Predicting the clinical efficacy of generic formulations of ceftriaxone.
Schito GC; Keenan MH
J Chemother; 2005 Sep; 17 Suppl 2():33-40. PubMed ID: 16315582
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
3. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
[TBL] [Abstract][Full Text] [Related]
4. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
Lodise TP; Nau R; Kinzig M; Jones RN; Drusano GL; Sörgel F
Diagn Microbiol Infect Dis; 2007 Aug; 58(4):445-52. PubMed ID: 17512154
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
[TBL] [Abstract][Full Text] [Related]
7. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae.
Bañón Arias R; García López M; Pinedo Sánchez A
J Chemother; 2001 Oct; 13(5):535-40. PubMed ID: 11760218
[TBL] [Abstract][Full Text] [Related]
8. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
[TBL] [Abstract][Full Text] [Related]
9. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis.
Fernández A; Cabellos C; Tubau F; Maiques JM; Doménech A; Ribes S; Liñares J; Viladrich PF; Gudiol F
J Antimicrob Chemother; 2005 Jan; 55(1):78-83. PubMed ID: 15546968
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antimicrobial treatments in children with acute otitis media in Spain: a pharmacokinetic-pharmacodynamic (PK/PD) approach.
Beobide I; Canut A; Gascón AR; Isla A; García-Rey C; De La Maza I; Labora A; Pedraz JL
J Chemother; 2005 Dec; 17(6):628-35. PubMed ID: 16433193
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists.
Ambrose PG
Pharmacotherapy; 2006 Jan; 26(1):129-34. PubMed ID: 16506354
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.
Isla A; Trocóniz IF; Canut A; Labora A; Martín-Herrero JE; Pedraz JL; Gascón AR
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):167-73. PubMed ID: 21334779
[TBL] [Abstract][Full Text] [Related]
13. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
Blumer JL; Reed MD; Kaplan EL; Drusano GL
Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Tasso L; de Andrade C; Dalla Costa T
Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
[TBL] [Abstract][Full Text] [Related]
15. Failure of a 5-day course of intramuscular ceftriaxone to eradicate Streptococcus pneumoniae from the middle ear.
Anon JB; Ripple WL; Jacobs MR
Pediatr Infect Dis J; 2006 Feb; 25(2):181-2. PubMed ID: 16462302
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of beta-lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin.
Pichardo C; Docobo-Pérez F; Pachón-Ibáñez ME; Jiménez-Mejías ME; García-Curiel A; Caballero-Granado FJ; Moreno-Maqueda I; Pachón J
J Antimicrob Chemother; 2005 Oct; 56(4):732-7. PubMed ID: 16150863
[TBL] [Abstract][Full Text] [Related]
17. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
[TBL] [Abstract][Full Text] [Related]
18. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
19. Penicillin and ceftriaxone susceptibility of Streptococcus pneumoniae isolated from cerebrospinal fluid of children with meningitis hospitalized in a tertiary hospital in Israel.
Waisbourd-Zinman O; Bilavsky E; Tirosh N; Samra Z; Amir J
Isr Med Assoc J; 2010 Apr; 12(4):225-8. PubMed ID: 20803882
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
